With the known association of the sporadic AD risk gene polymorphism APOE4 on BBB dysfunction, we utilized APOE4-carrying patient-derived iPSCs to generate a BBB-like model to test the effects of FUS+MB as well as the delivery of two therapeutic AD antibodies and compared the results to APOE3 (normal AD risk control) cells. This evidence concerns the gene APOE and Alzheimer disease.